Loading…
VivoSim Labs, Inc. is projected to decline to $0.767 by 2027, a -13% move from its current price of $0.879. VIVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.8399 | $0.8791 | $0.9202 | +0.01% |
| Jul 14 | $0.8243 | $0.8792 | $0.9379 | +0.03% |
| Jul 15 | $0.8125 | $0.8794 | $0.9518 | +0.04% |
| Jul 16 | $0.8027 | $0.8795 | $0.9636 | +0.06% |
| Jul 17 | $0.7942 | $0.8796 | $0.9742 | +0.07% |
| Jul 18 | $0.7866 | $0.8797 | $0.9839 | +0.08% |
| Jul 19 | $0.7797 | $0.8799 | $0.9929 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7797 | $0.8799 | $0.9929 | +0.10% |
| Week 2 | $0.7424 | $0.8807 | $1.04 | +0.20% |
| Week 3 | $0.7151 | $0.8816 | $1.09 | +0.30% |
| Week 4 | $0.693 | $0.8825 | $1.12 | +0.40% |
| Week 5 | $0.6742 | $0.8833 | $1.16 | +0.49% |
| Week 6 | $0.6577 | $0.8842 | $1.19 | +0.59% |
| Week 7 | $0.6429 | $0.8851 | $1.22 | +0.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
VivoSim Labs, Inc. (VIVS) is a healthcare company focused on testing drugs and drug candidates using three-dimensional (3D) human tissue models of liver and intestine. It provides liver and intestinal toxicology insights through its new approach methodologies (NAM) models and offers bespoke services across investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
The company also conducts liver toxicology predictive screening and studies the intestinal side effect profiles of therapeutic candidates at various stages of drug development, using proprietary technologies to build functional 3D human tissues that mimic key aspects of native tissue composition, architecture, function, and disease. In addition, it offers a 3D human tissue platform that develops novel normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The organization was formerly known as Organovo Holdings, Inc.
and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
VivoSim Labs, Inc. trades under the ticker VIVS. The current price is $0.879, and the stock sits in a smaller market niche with a market capitalization of $2.54M and a market rank of 5397.
The near-term outlook combines a bearish sentiment with a stock price that has traded within a 30-day range of $0.6505 to $1.19. Technical context shows RSI14 at 30, with a current price below both the SMA50 ($1.21) and SMA200 ($1.91). Support is identified at $0.78 and resistance at $1.35, framing a constrained near-term path.
A major floor 50.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.3% below — buyers have tended to step in here.
The nearest ceiling, 53.6% above — a clean break opens room to run.
A major ceiling 120.7% above — clearing it would confirm fresh momentum.
Key VIVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VIVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.87 | Buy | $0.8775 | Buy |
| MA 10 | $0.955 | Sell | $0.9369 | Sell |
| MA 20 | $1.04 | Sell | $1.02 | Sell |
| MA 50 | $1.21 | Sell | $1.20 | Sell |
| MA 100 | $1.47 | Sell | $1.43 | Sell |
| MA 200 | $1.91 | Sell | $1.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.79 | Neutral |
| Stoch RSI (14) | 77.42 | Neutral |
| CCI (20) | -115.33 | Sell |
| Williams %R (14) | -71.43 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -22.12 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 28.57 | Neutral |
| TRIX (15) | -1.03 | Sell |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 28.57 | Buy |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.77 | Buy |
| ADX (14) | 35.79 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day picture shows the price oscillating between $0.6505 and $1.19. The current price of $0.879 sits below the key near-term averages, with the SMA50 at $1.21 and the SMA200 at $1.91, implying continued near-term softness. The RSI of 30 reinforces a bearish tone, and the stock’s price action remains constrained by the $0.78 support and the $1.35 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.78 | $0.879 | $1.14 | 0% | Neutral | |
| $0.5725 | $0.767 | $1.11 | -13% | Neutral | |
| $0.6434 | $0.9064 | $1.38 | +3% | Neutral | |
| $0.8061 | $1.19 | $1.89 | +35% | Bullish | |
| $0.7356 | $1.12 | $1.86 | +28% | Bullish | |
| $0.6869 | $1.09 | $1.85 | +24% | Bullish | |
| $0.6324 | $1.04 | $1.81 | +18% | Neutral | |
| $0.5531 | $0.9349 | $1.68 | +6% | Neutral | |
| $0.6669 | $1.16 | $2.14 | +32% | Bullish | |
| $0.744 | $1.34 | $2.51 | +52% | Bullish | |
| $0.7126 | $1.48 | $3.02 | +68% | Bullish | |
| $1.21 | $2.68 | $6.16 | +205% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.78 | $0.879 | $1.11 | +0.00% |
| August 2026 | $0.7657 | $0.9202 | $1.15 | +4.69% |
| September 2026 | $0.732 | $0.8904 | $1.13 | -3.24% |
| October 2026 | $0.748 | $0.9192 | $1.18 | +3.24% |
| November 2026 | $0.7533 | $0.934 | $1.22 | +1.61% |
| December 2026 | $0.6902 | $0.8628 | $1.14 | -7.62% |
Click any year to see its month-by-month VIVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VIVS price prediction for 2026 points to an average of $0.879 (low $0.78, high $1.14) — a potential gain of 0% on today's $0.879. A consolidation phase looks the most probable path here.
In 2027, VIVS is projected to trade between $0.5725 and $1.11, averaging $0.767 — a potential decline of -13% from today's $0.879. That is -13% versus the projected 2026 average. Price action looks broadly range-bound.
VivoSim Labs, Inc.'s 2028 outlook centres on $0.9064, within a $0.6434 to $1.38 range. That is up +18% on the projected 2027 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, VIVS could reach as high as $1.89, with a base case around $1.19 and support toward $0.8061 — roughly +35% from $0.879. Momentum favours further upside here.
Expect VIVS to range from $0.7356 to $1.86 through 2030. The $1.12 average target implies a +28% move from current prices. That is -5% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The VIVS price prediction for 2031 points to an average of $1.09 (low $0.6869, high $1.85) — a potential gain of +24% on today's $0.879. Momentum favours further upside here.
In 2032, VIVS is projected to trade between $0.6324 and $1.81, averaging $1.04 — a potential gain of +18% from today's $0.879. That is -5% versus the projected 2031 average. A consolidation phase looks the most probable path here.
VivoSim Labs, Inc.'s 2033 outlook centres on $0.9349, within a $0.5531 to $1.68 range. That is -10% versus the projected 2032 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2034, VIVS could reach as high as $2.14, with a base case around $1.16 and support toward $0.6669 — roughly +32% from $0.879. Buyers look set to stay in control over this stretch.
Expect VIVS to range from $0.744 to $2.51 through 2035. The $1.34 average target implies a +52% move from current prices. That is up +15% on the projected 2034 average. Momentum favours further upside here.
The VIVS price prediction for 2040 points to an average of $1.48 (low $0.7126, high $3.02) — a potential gain of +68% on today's $0.879. Buyers look set to stay in control over this stretch.
In 2050, VIVS is projected to trade between $1.21 and $6.16, averaging $2.68 — a potential gain of +205% from today's $0.879. That is up +81% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VIVS today (≈ 1,137.656428 VIVS) could be worth
$3,048.38
+$2,048.38 (+205%) by 2050 · US Dollar
Based on the average projected VIVS price of $2.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VIVSwould be worth at today's price.
$1,000 invested in VIVS on Jul 10, 2025 (≈ 507.614206 VIVS) would be worth
$446.19
-$553.81 (-55.4%) today · 0.45× · US Dollar
Based on a VIVS entry price of $1.97 vs. today's $0.879.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.98 | $896.94 | -10.3% |
| 1 month ago | $1.18 | $744.92 | -25.5% |
| 3 months ago | $1.45 | $606.21 | -39.4% |
| 6 months ago | $2.02 | $435.15 | -56.5% |
| 1 year ago | $1.97 | $446.19 | -55.4% |
| All time (5.0y) ago | $98.04 | $8.97 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VIVS forecast.
Our base-case forecast reaches $1.80 around 2050.
Implied market cap at $1.80: $5.21M
The multi-year forecast depicts a gradual rise in average prices across later years, with notable bullish momentum developing through the 2030s and beyond. In 2030, the forecast shows an average price of $1.13 with a 28% ROI, after earlier years’ mixed moves. By 2035 the average is projected at $1.34 with a 52% ROI, and by 2040 the average rises to $1.48 with a 68.2% ROI.
The long-run outlook extends to 2050 with an average of $2.67 and a 204% ROI, with the max price forecast reaching $6.15. The forecast also highlights that 2027 could see a negative ROI of -12.6%, while 2029 and 2034–2035 show meaningful upside, culminating in significant longer-term gains but with evident volatility along the way. These figures reflect estimates, not guarantees.
The sentiment shifts toward bullish in the later years (2030, 2040, 2050), but the path includes periods of lower or negative returns and inherent investment risk.
Tap a question to reveal the answer.
2030 avg price is $1.13 with a 28% ROI; the 2030 forecast also shows a min of $0.7364 and a max of $1.86.
Current price is $0.879 with a market cap of $2.54M and bearish near-term sentiment. The forecast shows a path of variable returns, including a bullish outlook in 2029 onward and a strong long-run potential, but there is also risk of negative or lower returns in some years.
Yes. The forecast max by 2040 is $3.02 and by 2050 is $6.15, with the 2040 max exceeding $3.00.
The 30-day range spans $0.6505 to $1.19. RSI14 is 30, and price is below the SMA50 of $1.21 and the SMA200 of $1.91, with support at $0.78 and resistance at $1.35.
The market capitalization is $2.54M, with a rank of 5397.
VivoSim Labs, Inc. Community Discussion
0Share your VivoSim Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.